Neurocrine Biosciences and Voyager Therapeutic announced the formation of a strategic collaboration focused on the development and commercialization of Voyager’s gene therapy programs, VY-AADC for Parkinson’s disease and VY-FXN01 for Friedreich’s ataxia, as well as rights to two programs to be determined. This collaboration combines Neurocrine Biosciences’ expertise in neuroscience, drug development and commercialization with Voyager’s innovative gene therapy programs targeting severe neurological diseases.

Read the entire article HERE

VYGR (NASDAQ)                                                                                NBIX (NASDAQ)
Siège social : Massachusetts, États-Unis                            Siège social : San Diego, Californie, États-Unis